A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia


Gemici A., ÖZKALEMKAŞ F., Dogu M. H. , Tekinalp A., ALACACIOĞLU İ., Guney T., ...More

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.8, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 8
  • Publication Date: 2021
  • Doi Number: 10.1016/j.clml.2021.04.004
  • Title of Journal : CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Keywords: Bcl2, Inhibitor, Venetoclax, Acute myeloid leukemia, Real life, LOW-DOSE CYTARABINE, OLDER PATIENTS, BCL-2 INHIBITION, AZACITIDINE, SURVIVAL, CARE, AML

Abstract

Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.